Our COVID-19 Response Efforts
Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND)'s core focus areas contribute to building a more lethal force, a priority in the National Defense Strategy, and streamline JPEO-CBRND efforts to meet the Joint Service’s needs in combating chemical, biological, radiological and nuclear (CBRN) threats.
JPEO-CBRND is supporting our interagency partners in their response to the COVID-19 pandemic, from helping develop detection, diagnosis, treatment, and vaccines for our Warfighters, to tools that increase situational awareness of the coronavirus, all thanks to our team effort with industry and academia.
Fact Sheets
Press Releases and Media
- DOD Awards University of Louisville $8.5 Million for COVID-19 Q-Griffithsin Repurposing Effort
- JPM CBRN Medical Tiger Team Takes Bold Action to Support Pandemic Response
- SAB Biotherapeutics Awarded $57.5M from BARDA and U.S. Department of Defense for Manufacturing of SAB-185 for the Treatment of COVID-19
- DARPA and JPEO Award Contract to SmartPharm, a Subsidiary of Sorrento, for Development of Rapid Countermeasure Against COVID-19 Using Gene-Encoded Neutralizing Antibodies
- Ology Bioservices Awarded $37 Million by Department of Defense for Advanced Development of Anti-COVID-19 Monoclonal Antibody Cocktail
- HHS, DOD Collaborate on Plans to Purchase of Lilly Investigational Therapeutic to Treat COVID-19
- DOD-Funded Drug Remdesivir Receives FDA Approval for COVID-19 Treatment
- Trump Administration Expands Manufacturing Capacity with Cytiva for Components of COVID-19 Vaccines
- Trump Administration Expands Collaboration With AstraZeneca to Develop and Manufacture an Investigational Monoclonal Antibody to Prevent COVID-19
- DOD Awards $481 Million Other Transaction Agreement (OTA) to Cue Health to Increase Domestic Production Capacity of Point-of-Care Testing
- DOD Awards Goldbelt Security, LLC, $125 Million in Support of National COVID-19 Vaccination Strategy
- DOD Sites Selected for Phase III COVID-19 Vaccine Trials: Five Medical Treatment Facilities in National Capital Region, San Antonio, and San Diego to Participate
- DOD Awards $750,000 to Plasma Technologies, LLC for Manufacturing of Convalescent Plasma Products Using a Novel Process in Support of the U.S. COVID-19 Response
- DOD Awards $104 Million for Procurement of Syringes in Support of U.S. COVID-19 Vaccination Campaign
- DOD Awards Johns Hopkins University $35 Million for COVID-19 Convalescent Plasma Research
- HHS, DOD Collaborate With Johnson & Johnson to Produce Millions of COVID-19 Investigational Vaccine Doses
- DOD Awards Partner Therapeutics $35 Million for Repurposing and Emergency Use of Leukine for COVID-19 Treatment
- JBADS Lite: Decon at the Speed of Relevance
- HHS, DOD Partner With Sanofi and GSK on Commercial-Scale Manufacturing Demonstration Project to Produce Millions of COVID-19 Investigational Vaccine Doses
- DOD Awards Industry Partner Immunome $13.3 Million for Biosynthetic Convalescent Plasma Development
- BARDA and JPEO-CBRND establish partnership with Retractable Technologies, Inc. to expand the capacity to manufacture needles and syringes in the US
- BARDA and JPEO-CBRND establish partnership with Becton Dickinson to expand domestic manufacturing capacity for needles and syringes
- HHS, DOD Collaborate with Novavax to Produce Millions of COVID-19 Investigational Vaccine Doses in Commercial-Scale Manufacturing Demonstration Projects
- HHS, DOD Collaborate with Regeneron on Large-Scale Manufacturing Demonstration Project of COVID-19 Investigational Therapeutic Treatment
- U.S. Government Engages Pfizer to Produce Millions of Doses of COVID-19 Vaccine
- JPEO-CBRND Works with Industry to Develop COVID-19 Diagnostic Tests
- Kratos Mobile Laboratory Product Supporting COVID-19 Response Efforts
- MRI Global to Deliver Three Mobile Medical Labs with $2 Million DOD Contract
- 60 Minutes: Fighting an unseen enemy: How the military is protecting itself from the coronavirus pandemic
- AFLCMC led team delivers isolation container prototype for testing
- PhysIQ, Department of Defense, and The Henry M. Jackson Foundation for the Advancement of Military Medicine Partner to Deploy Continuous Remote Monitoring Platform to Study COVID-19
- Ology Bioservices to Adapt Veroplex® Cell Platform for Rapid Response to Viral Threats for Department of Defense
- SAB Biotherapeutics Advances Therapeutic for COVID-19 in Partnership with Department of Defense and BARDA
- SAB Biotherapeutics Awarded $27M Contract to Develop Novel Rapid Response Capability for U.S. Department of Defense
- DOD OTA Agreement Leveraged by Interagency for COVID-19 Rapid Response
- DOD-Funded Diagnostic Test for COVID-19 Granted Emergency Use Authorization
- DOD OTA Agreement Leveraged by Interagency for COVID-19 Rapid Response
- Ology Bioservices, Inovio Partner To Manufacture COVID-19 DNA Vaccine With $11.9 Million Department of Defense Grant
- Ology
Bioservices, Vanderbilt University Medical Center to Develop,
Manufacture Monoclonal Antibody for Treatment, Prevention of Infection
With COVID-19 Virus for Department of Defense
- DOD Leveraging Diagnostic Platform for COVID-19 Rapid Response
- Coronavirus Pandemic Solutions Sought by Government
